Phase 2b Study Evaluates KT-621 for Moderate to Severe Eosinophilic Asthma

This Phase 2b study, sponsored by Kymera Therapeutics, Inc., is currently recruiting to evaluate the safety and efficacy of KT-621 in adults with uncontrolled moderate to severe eosinophilic asthma. The trial aims to enroll 264 participants and will focus on assessing the change from baseline in pre-bronchodilator FEV1 as the primary outcome. The study will also investigate the safety, tolerability, and pharmacokinetics of KT-621. The trial started on January 28, 2026, with a primary completion date set for December 2027. The study's design includes a comparison between KT-621 and a placebo to determine the drug's effectiveness and safety profile in the specified patient population.

If you or someone you know struggles with moderate to severe eosinophilic asthma, a new study is looking into a promising treatment called KT-621. This Phase 2b study aims to find out how effective KT-621 is in helping people breathe better when their asthma is not well controlled. It will also assess the safety and tolerability of the drug, which means how well patients can handle it without serious side effects. The main focus is on measuring lung function improvement, specifically looking at a test called FEV1, which shows how much air you can forcefully exhale in one second. With an estimated 264 participants, this research could provide valuable insights for those who feel like their asthma is holding them back. If KT-621 proves effective, it could offer new hope for better asthma management.